The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate (ADC) that saw three fatalities after the companies confirmed that only lower doses will be used.

Israeli biotech SciSparc has sold the license for its cannabinoid receptor type 2 (CB2R) agonist to its partner Polyrizon to further develop as a pain therapy.

The gastrointestinal device and robotics developer Neptune Medical announced it has raised $97 million in venture capital funds—and that it’s launched another subsidiary into its orbit.

Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.

Lykos Therapeutics is capping off an awful week with a massive reorganization, laying off about 75% of staff in the aftermath of an FDA rejection and the retraction of three research papers on the biotech’s MDMA treatment due to protocol violations at a clinical trial site.

After collecting a de novo clearance from the FDA last fall for its ultrasound-powered liver cancer treatment, HistoSonics has raised $102 million in funds to turn up the volume on its commercial efforts.

Two and half years after it signed a $100 million biobucks deal with Aarvik Therapeutics to work on an undisclosed “novel oncology drug,” ArriVent BioPharma has decided to license the candidate—and confirmed that it’s an antibody-drug conjugate (ADC).

Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million.

As Grail finally leaves the Illumina nest, taking flight as a public, independent company for the first time, the cancer blood test developer said it would shed as much as 30% of its staff and narrow its focus to help it gain altitude on a single, primary objective.

Galera Therapeutics is shuttering, with the biotech’s board OK’ing a liquidation plan that whittles down the company’s workforce to just three people.